Knowledge Base

Research Articles

Explore our collection of in-depth research articles, literature reviews, and educational guides on peptide science.

82 articles
Filter:All ArticlesHealing & RecoveryGrowth HormoneCognitive EnhancementMetabolic PeptidesAntimicrobial Peptides+11 more
Research15 min

FOXO4-DRI: The Senolytic Peptide That Targets 'Zombie Cells' — And What the Latest Research Shows

Your body is accumulating cells that refuse to die and refuse to do their jobs — secreting inflammatory signals that accelerate aging across every organ. FOXO4-DRI is the precision peptide engineered to eliminate them. Here's what eight years of research actually shows.

Anti-Aging & Longevity
Research14 min

Orforglipron: The GLP-1 Pill That Isn't a Peptide — And Why That Changes Everything

Eli Lilly's orforglipron could become the first non-peptide oral GLP-1 drug approved by the FDA. With a PDUFA date of April 2026, NEJM-published Phase 3 data showing 11.2% weight loss, and head-to-head superiority over oral semaglutide, here's what the clinical evidence actually says — and why a small molecule beating peptides at their own game matters more than you think.

Metabolic Peptides
News14 min

14 Peptides Are Legal Again: What the RFK Reclassification Actually Means

In February 2026, HHS Secretary RFK Jr. announced that 14 peptides—including BPC-157, Thymosin Alpha-1, and CJC-1295/Ipamorelin—would return to legal compounding status. Here's what changed, what didn't, and what it means for the peptide community going forward.

Regulation & Policy
Research14 min

CagriSema: The Amylin-GLP-1 Combo That Could Change the Weight Loss War

Novo Nordisk's CagriSema pairs an amylin analog with semaglutide to attack appetite from two directions at once. With 22.7% weight loss in Phase 3, an FDA filing already submitted, and a dramatic head-to-head showdown against tirzepatide, here's what the clinical data actually shows.

Metabolic Peptides
Research15 min

Survodutide and MASH: The Dual Agonist Taking Aim at the Liver Disease Epidemic

With up to 62% of patients achieving MASH resolution in Phase 2 trials—roughly double the only approved drug—Boehringer Ingelheim's GLP-1/glucagon dual agonist could reshape how we treat the world's most common liver disease. Here's what the data shows.

Metabolic Peptides
Research16 min

AI-Driven Peptide Discovery: How Machine Learning Is Redesigning the Drug Pipeline

From generative models designing antimicrobial peptides in hours to the first AI-designed peptide entering human clinical trials, artificial intelligence is fundamentally reshaping how peptide therapeutics are discovered, optimized, and brought to patients.

Peptide Education
Research16 min

Retatrutide: The Triple Agonist That's Rewriting the Weight Loss Playbook

With nearly 29% average weight loss in trials—double what Ozempic delivers—Eli Lilly's triple hormone agonist is generating massive buzz. Here's what the science actually shows, when it might be available, and what those online discussions aren't telling you.

Metabolic Peptides
Research14 min

GLP-1 and Addiction: Can Ozempic Really Cure Your Cravings?

Thousands of patients report losing interest in alcohol, gambling, and even shopping after starting GLP-1 drugs. The science behind these claims is both promising and complicated—and it's reshaping how we think about addiction.

Metabolic Peptides
Research12 min

Personalized Neoantigen Peptide Vaccines: The Future of Cancer Immunotherapy

Personalized cancer vaccines using tumor-specific peptide neoantigens represent one of the most promising frontiers in oncology. With Phase 1 trials showing 5-year survival data and no recurrences in high-risk patients, this emerging technology is transforming our approach to treating cancer.

Immune Modulation

Showing 1-9 of 82 articles

Jump to:
FirstPage 5Last

Looking for specific peptide data?

Browse our comprehensive peptide database with molecular information and research status.

Peptide Database